Ginkgo Bioworks Holdings Class A (DNA) closed at $12.01 on November 10, 2026, down 2.9% from the previous close, on volume of 1,407,986 shares (30-day average 3,259,995).
Data as of November 10, 2026.
10-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 14, 2026 | Call Spread | 19-Mar-2725 : 26 C | 206 |
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 9, 2026. See the 10 largest for 30, 60 and 90 days
Business Wire (Thu, 5-Nov 4:05 PM ET)
Ginkgo Bioworks Adds 1536-Well Imaging Under Four Minutes to Nebula’s Autonomous Lab Workflow
Market Chameleon (Fri, 9-Oct 7:05 AM ET)
Business Wire (Thu, 8-Oct 4:10 PM ET)
Araceli Biosciences and Ginkgo Bioworks Bring Cellular Imaging at Scale to Nebula's Lab-in-the-Loop
PRNewswire (Thu, 8-Oct 6:01 AM ET)
Business Wire (Tue, 29-Sep 8:08 AM ET)
Ginkgo Datapoints Announces Partnership with TuneLab to Close the Gap between AI Models and Lab Data
Business Wire (Wed, 16-Sep 9:52 AM ET)
Business Wire (Thu, 10-Sep 8:00 AM ET)
Ginkgo Bioworks Refocuses on Autonomous Labs as Biosecurity Divestiture Reshapes Strategy
Market Chameleon (Fri, 27-Feb 2:33 AM ET)
Market Chameleon (Fri, 6-Feb 2:06 AM ET)
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.
Ginkgo Bioworks Holdings Class A trades on the NYSE stock market under the symbol DNA.
As of November 10, 2026, DNA stock price declined to $12.01 with 1,407,986 million shares trading.
DNA has a beta of 2.53, meaning it tends to be more sensitive to market movements. DNA has a correlation of 0.12 to the broad based SPY ETF.
DNA has a market cap of $808.76 million. This is considered a Small Cap stock.
Last quarter Ginkgo Bioworks Holdings Class A reported $28 million in Revenue and -$.64 earnings per share. This beat revenue expectation by $6 million and missed earnings estimates by -$.09.
In the last 3 years, DNA traded as high as $75.20 and as low as $5.00.
The top ETF exchange traded funds that DNA belongs to (by Net Assets): VTI, IWM, VXF, IWN, THNQ.
DNA has outperformed the market in the last year with a price return of +34.2% while the SPY ETF gained +12.9%. DNA has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +50.7% and +19.9%, respectively, while the SPY returned -2.8% and -2.0%, respectively.
DNA support price is $11.37 and resistance is $13.37 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that DNA shares will trade within this expected range on the day.
